Intra-Cellular Says Phase3 Trial Study 502 Of Lumateperone In MDD Meets Primary Endpoint

Biopharmaceutical company Intra-Cellular Therapies, Inc. (ITCI) announced Tuesday positive topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder (MDD). This trial, in conjunction with the previously reported positive Phase 3 study, Study 501, forms the basis for lumateperone sNDA for the adjunctive...

Read More

Canadian Market Remains Weak In Lackluster Trade

The Canadian market is down in negative territory Wednesday afternoon, weighed down by losses in industrials, financials and consumer staples sectors. With the U.S. markets closed for Juneteenth holiday, and no big economic data to trigger any significant moves, the market is struggling for direction. The benchmark S&P/TSX Composite Index is down 111.72 points at...

Read More